Add To Watchlist
Share URL
About The Company
Description
Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden.
Read More
Overview
Value
1
Growth
33
Health
24
Management
35
Analyst Opinion
63
Total
31
All Scores Out Of 100
Best Features
- Has a low level of debt
- Low preportion of income is paid as dividend
Risk Factors
- Overvalued on cashflow basis
- Earnings have declined recently
- Income is not covering expenditure and investment
- Earnings are negative
- Poor overall financial health
- No margin of safety at their current market price
- Poor earnings and cashflow growth 0
Market Peers
LIPUM.ST
Key Figures
PE Ratio (TTM)
N/A
Margin Of Safety (DCF)
-217.85%
Revenue Growth (5 Year Average)
N/A
Ratings Consensus
Neutral
Share Buybacks
N/A
Dividend Yeild (TTM)
N/A
Valuation
Value Score
1
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Buy Target: N/A✘
Current Price: 10.5 SEK
Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.
Price/Earnings
N/Ax
Free Cashflow Yeild
-65.47%
PE/Earnings Growth
N/A
Price/Book
27.02x
Growth
Growth Score
33
- ✔ 5 Year Average Earnings growth of 15.27% is higher than the market average (14.48%)
- ✘ 5 Year Average Revenue growth of N/A is lower than the market average (10.97%)
- ✘ Revenue growth has slowed this year
- ✘ Earnings growth has slowed this year
- ✘ 5 Year Average Free Cashflow growth of -0.78% is lower than the market average (12.35%)
- ✘ Free Cashflow growth has slowed this year
Revenue Growth
N/A
Earnings Growth
15.27%
Cashflow Growth
-0.78%
Health
Health Score
24
Altman Z Score
N/A
Piostroski Score
N/A
Debt/Equity
0.53x
Current Assets/Liabilities
1.74x
Free Cashflow/Total Debt
N/Ax
Debt/Capital
0.15x
Management
Management Score
35
Average Buybacks/Dilution
N/A
Recent Buybacks/Dilution
51.49%
5 Year Price Volitility
18.43%
Return On Assets
-119.54%
Return On Capital Employed
-53.05%
Return On Equity
-504.35%
Return On Free Cashflow
162.52%
Return On Investments
N/A
Analysts
Analyst Opinion
63
- ✔ Ratings consensus is Neutral
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
Other Information
Company Name
Currency
SEK
Beta
Vol Avg
Ceo
Dr. Einar Ponten
Cik
Cusip
Exchange
Stockholm Stock Exchange
Full Time Employees
Industry
Biotechnology
Sector
Healthcare
Ipo Date
Address
Tvistevägen 48C
City
Umeå
State
Country
Zip
907 36
Phone
46 9 03 40 34 30
All financial data provided by FMP